The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Severe Depression, Suicide Attempts, and Ideation During the Use of Interferon Beta by Patients With Multiple Sclerosis
Abstract
BACKGROUND: Interferon (IFN) beta is a safe and efficient drug for treating multiple sclerosis (MS). It is widely accepted that previously depressed patients may get worse when using IFN-beta. There are few reports on the association of IFN-beta and severe depression among patients without previous psychiatric history. METHODS: Discussion of a case of a patient with MS who developed severe depression and attempted suicide while using IFN-beta encouraged us to review the subject. A group of neurologists in Brazil retrospectively gathered together their similar cases for the present paper. RESULTS: The present paper reports on 11 cases of severe depression with suicide attempts or ideation among patients with MS who were using IFN-beta. These patients had no previous history of any psychiatric disease. Nine patients developed the symptoms over a relatively short period (4 months, on average). Two patients developed severe depression after more than 1 year of treatment with IFN-beta. Phobic, aggressive, behavioral, psychotic, and manic symptoms also were observed in these patients, thus suggesting the existence of a complex mood-behavior disorder associated with this drug. Interferon beta withdrawal led to complete remission of symptoms. The Naranjo algorithm established a highly probable association between IFN-beta and this adverse reaction in these patients. CONCLUSIONS: Although uncommon, severe depression with suicide ideation or attempts may be observed during treatment of MS with IFN-beta. This association should not discourage the use of this drug, but physicians need to be aware of this possible adverse event from IFN-beta.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and in patients receiving pro-inflammatory cytokines for the treatment of multiple sclerosis.[19]”
From SUICIDAL IDEATION IS ASSOCIATED WITH ELEVATED INFLAMMATION IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER: Research Article: Suicidal Ideation and Inflammation (2013) · cites this paper as [19]
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Raison, C. L., Dantzer, R., Kelley, K. W., Lawson, M. A., Woolwine, B. J., Vogt, G., Spivey, J. R., Saito, K., & Miller, A. H. (2010) · Molecular Psychiatry · doi:10.1038/mp.2009.116 · Cited by 630
Neuropsychiatric Adverse Effects of Interferon-??: Recognition and Management
Raison, C. L., Demetrashvili, M., Capuron, L., & Miller, A. H. (2005) · CNS Drugs · doi:10.2165/00023210-200519020-00002 · Cited by 483
Multiple sclerosis beyond EDSS: depression and fatigue.
Ziemssen, T. (2009) · Journal of Neurological Sciences · doi:10.1016/s0022-510x(09)70011-5 · Cited by 168
Interferon in relapsing-remitting multiple sclerosis
Rice, G. P., Incorvaia, B., Munari, L., Ebers, G. C., Polman, C. H., D’Amico, R., Parmelli, E., & Filippini, G. (2001) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002002 · Cited by 146
Neuropsychiatric disorders related to interferon and interleukins treatment
Myint, A. M., Schwarz, M. J., Steinbusch, H. W. M., & Leonard, B. E. (2009) · Metabolic Brain Disease · doi:10.1007/s11011-008-9114-5 · Cited by 116
Multiple Sclerosis, interferon beta-1b and depression
Feinstein, A., O’Connor, P., & Feinstein, K. (2002) · Journal of Neurology · doi:10.1007/s00415-002-0725-0 · Cited by 103
Psychiatric side effects of interferon-β in multiple sclerosis
Goëb, J.-L., EVEN, C., Nicolas, G., Gohier, B., Dubas, F., & Garré, J.-B. (2005) · European Psychiatry · doi:10.1016/j.eurpsy.2005.09.013 · Cited by 96
Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study
Fermo, S. L., Barone, R. M. E., Patti, F., Laisa, P., Cavallaro, T. L., Nicoletti, A. S. Q., & Zappia, M. (2010) · Multiple Sclerosis Journal · doi:10.1177/1352458510365157 · Cited by 79
Research works printed but not linked: 1
- Naranjo, 1981, Empirical delineation of the probability spectrum of adverse drug reactions., Clin Pharmacol Ther, 29, 267
Cited by
Sorted by citations
Items 101–116 of 116
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.004
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.011
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.007
I Think, Therefore I Do Not Want to Be
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.006
Suicide as a Systemic Disorder
Lengvenytė, A., Olié, É., & Courtet, P. (2021) · Springer eBooks · doi:10.1007/978-3-030-71229-7_19
(2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.013
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.015
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.001
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.005
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.012
van Heeringen, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316563205.014
A clinical case of multiple sclerosis with an episode of schizophrenia-like syndrome
Kuzmina, U. S., Tukhvatullin, A. V., Bakhtiyarova, K. Z., Kutlubaev, M. A., Lyutov, O. V., & Рафаилович, Г. Т. (2023) · S S Korsakov Journal of Neurology and Psychiatry · doi:10.17116/jnevro2023123041120
Nasopharyngeal Carcinoma in Pediatric and Adolescent Patients
Uğurluer, G., Mustafayev, T. Z., & Özyar, E. (2023) · Medical radiology · doi:10.1007/174_2023_462
Гематологические коэффициенты системного воспаления как потенциальные биомаркеры суицида
Gorbunova, A. P., Rukavishnikov, G. V., Kasyanov, E. D., Kibitov, A. O., & Mazo, G. E. (2024) · Суицидология · doi:10.32878/suiciderus.24-15-01(54)-31-52
Barbieri, C., Violante, M. G., Risola, R., Leo, A. D., Pagani, K., Cassano, A., Bosco, C., Grattagliano, I., & Vella, G. D. (2025) · Journal of Forensic Sciences · doi:10.1111/1556-4029.70115
Olejnik, P., Prisco, A., Menchetti, M., & Kasarełło, K. (2026) · Journal of Neural Transmission · doi:10.1007/s00702-026-03180-6
Metadata
- Authors
- Fragoso, Y. D., Frota, E. R. C., Lopes, J. S., Noal, J. S., Giacomo, M. C., Gomes, S., Gonçalves, M. V. M., da Gama, P. D., & Finkelsztejn, A.
- Affiliations
- Beneficência Portuguesa de São Paulo (BR)
- Hospital de Clínicas de Porto Alegre (BR)
- Corresponding author
- Finkelsztejn, Alessandro
- Venue
- Clinical Neuropharmacology
- Published
- 2010-11
- Volume
- 33
- Issue
- 6
- Pages
- 312-316
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2018025671
- Cited by
- 116
- References
- 24
- Citations by year
- 2026: 1 · 2025: 6 · 2024: 3 · 2023: 7 · 2022: 3 · 2021: 10 · 2020: 6 · 2019: 4 · 2018: 18 · 2017: 4 · 2016: 10 · 2015: 12 · 2014: 9 · 2013: 7 · 2012: 9
- FWCI
- 4.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- interferon-beta, multiple sclerosis, severe depression, suicide attempts, suicidal ideation, adverse drug reactions, interferon withdrawal, Naranjo algorithm, psychiatric adverse effects
- MeSH terms
- Adult, Brazil, Depressive Disorder, Female, Humans, Interferon Type I, Male, Middle Aged, Multiple Sclerosis, Recombinant Proteins, Suicide, Attempted, Prevalence, Treatment Outcome, Drug Monitoring, Mood Disorders, Young Adult, Suicidal Ideation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
